2020
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Kato S, Kim K, Lim H, Boichard A, Nikanjam M, Weihe E, Kuo D, Eskander R, Goodman A, Galanina N, Fanta P, Schwab R, Shatsky R, Plaxe S, Sharabi A, Stites E, Adashek J, Okamura R, Lee S, Lippman S, Sicklick J, Kurzrock R. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications 2020, 11: 4965. PMID: 33009371, PMCID: PMC7532150, DOI: 10.1038/s41467-020-18613-3.Peer-Reviewed Original ResearchConceptsMolecular tumor boardOverall survivalTumor boardNext-generation sequencingReviewed patient characteristicsResistant to monotherapyProgression-freeOncological outcomesRemission rateChoice regimenGenomic alterationsPatient characteristicsRecommended drugsMolecular findingsPatientsTherapyMaster protocolCancer targetPhysician-directedPFSPrecision strategySurvivalDrugMedication accessOutcomes
2018
Tumour-immune dynamics with an immune checkpoint inhibitor
Nikolopoulou E, Johnson L, Harris D, Nagy J, Stites E, Kuang Y. Tumour-immune dynamics with an immune checkpoint inhibitor. Letters In Biomathematics 2018, 5: s137-s159. DOI: 10.1080/23737867.2018.1440978.Peer-Reviewed Original ResearchProteins programmed death-1Anti-PD-1Immune checkpoint inhibitorsTumor-immune dynamicsCheckpoint inhibitorsAnti-PD-1 drugsLigand PD-L1Eradicate tumor cellsTumor immune responseFunctional immune systemAntitumour responseDeath-1PD-L1Tumor-freeControl tumorsTumor equilibriumTumor cellsClinical trialsContinuous treatmentImmune systemTreatmentTumor-immune modelInhibitorsTumorTherapy